Evidence map›Paper›PMID 25051962›Full record

ArticleBlood2014

Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD.

Ahmad Khoder, Anushruti Sarvaria, Abdullah Alsuliman, Claude Chew, Takuya Sekine, Nichola Cooper, Stephan Mielke, Hugues de Lavallade, Muharrem Muftuoglu, Irina Fernandez Curbelo and 15 more

Abstract read
In one paragraph

Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
120citing papers in PubMed, 1 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

120 citing papers in PubMed, 1 synthesis or guideline pooled it, 202 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015
    Trial
  5. Chronic graft-versus-host disease.Nature reviews. Disease primers · 2026
    Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Therapeutic efficacy of rituximab combined with cyclosporin A on B-cell dysregulation in chronic graft-versus-host disease.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Article
  11. PD-L1International journal of molecular sciences · 2025
    Article
  12. Expansion of B10 cellsInternational journal of molecular medicine · 2025
    Review
  13. Article
  14. Article
  15. Ex vivo-generated human CD1cMolecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

60 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 3 countries.

Ahmad KhoderDepartment of Haematology, Imperial College London, Hammersmith Campus, London, United Kingdom;
Anushruti SarvariaStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Abdullah AlsulimanDepartment of Haematology, Imperial College London, Hammersmith Campus, London, United Kingdom;
Claude ChewStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Takuya SekineStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Nichola CooperDepartment of Haematology, Imperial College London, Hammersmith Campus, London, United Kingdom;
Stephan MielkeUniversity of Wuerzburg, Wuerzburg, Germany;
Hugues de LavalladeDepartment of Haematology, Imperial College London, Hammersmith Campus, London, United Kingdom;
Muharrem MuftuogluStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Irina Fernandez CurbeloStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Enli LiuStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Paolo A MuraroDivision of Brain Sciences, Imperial College London, United Kingdom;
Amin AlousiStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Kate StringarisDepartment of Haematology, Imperial College London, Hammersmith Campus, London, United Kingdom;
Simrit ParmarStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Nina ShahStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Hila ShaimStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Eric YvonStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Jeffrey MolldremStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Rayne RouceBaylor College of Medicine. Houston, TX; and.
Richard ChamplinStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Ian McNieceStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Claudia MauriUniversity College, London, United Kingdom.
Elizabeth J ShpallStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
Katayoun RezvaniStem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Centre, Houston, TX;
The University of Texas MD Anderson Cancer Center · USImperial College London · GBBaylor College of Medicine · USUniversity College London · GBUniversity of Würzburg · DE

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Kathrin Milbury · 1985 to 2026
$290.8M
University of Texas M.D. Anderson Cancer SPORE-LeukemiaP50CA100632 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HUANG, XUELIN · 2003 to 2023
$43.7M
PR1-specific CB T cells for Patients with Myeloid MalignanciesP01CA148600 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI SHPALL, ELIZABETH J · 2011 to 2022
$24.4M
NCI NIH HHS CA016672NCI NIH HHS P01 CA148600NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA100632Versus Arthritis 17707Versus Arthritis 19314
6 · The paper itself

Abstract

A subset of regulatory B cells (Bregs) in mice negatively regulate T-cell immune responses through the secretion of regulatory cytokines such as IL-10 and direct cell-cell contact and have been linked to experimental models of autoimmunity, inflammation, and cancer. However, the regulatory function of Bregs in human disease is much less clear. Here we demonstrate that B cells with immunoregulatory properties are enriched within both the CD19(+)IgM(+)CD27(+) memory and CD19(+)CD24(hi)CD38(hi) transitional B-cell subsets in healthy human donors. Both subsets suppressed the proliferation and interferon-γ production of CD3/CD28-stimulated autologous CD4(+) T cells in a dose-dependent manner, and both relied on IL-10 secretion as well as cell-cell contact, likely mediated through CD80 and CD86, to support their full suppressive function. Moreover, after allogeneic stem cell transplantation, Bregs from patients with chronic graft-versus-host disease (cGVHD) were less frequent and less likely to produce IL-10 than were Bregs from healthy donors and patients without cGVHD. These findings suggest that Bregs may be involved in the pathogenesis of cGVHD and support future investigation of regulatory B cell-based therapy in the treatment of this disease.

Indexed as

Immunologic MemoryADP-ribosyl Cyclase 1Antigens, CD19B7-1 AntigenB7-2 AntigenB-Lymphocytes, RegulatoryB-Lymphocyte SubsetsCase-Control StudiesCD24 AntigenCD4-Positive T-LymphocytesCell CommunicationCells, CulturedChronic DiseaseCytokinesGraft vs Host DiseaseHumansADP-ribosyl Cyclase 1Antigens, CD19B7-1 AntigenB7-2 AntigenCD24 AntigenCytokinesImmunoglobulin MInflammation MediatorsInterleukin-10Tumor Necrosis Factor Receptor Superfamily, Member 7

Identifiers

PMID25051962
PMCPMC4186534
OpenAlexW2039025802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.